Alvotech (ALVO) vs Immunocore (IMCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Immunocore (IMCR) has outperformed Alvotech (ALVO) over the past year, losing 12.9% versus a loss of 30.4%. Alvotech is the larger company by market cap ($2.06 billion vs $1.51 billion), about 1.4 times the size, while Immunocore is growing revenue faster (+29.0% vs +19.7%). Alvotech converts more of its revenue into profit, with a net margin of 4.8% versus -8.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALVO | IMCR |
|---|---|---|
| Share price | $5.78 | $29.39 |
| Market cap | $2.06B | $1.51B |
| 1-day change | +1.94% | +1.03% |
| YTD return | +12.67% | -15.33% |
| 1-year return | -30.36% | -12.94% |
| 5-year return | — | -22.66% |
| Forward P/E | 25.32 | — |
| EPS (TTM) | $-0.62 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $586.32M | $400.02M |
| Revenue growth (YoY) | +19.74% | +28.95% |
| Net income (latest FY) | $27.92M | $-35.51M |
| Gross margin | 59.82% | 98.73% |
| Operating margin | 13.34% | -11.34% |
| Net margin | 4.76% | -8.88% |
| 52-week high | $9.05 | $40.72 |
| 52-week low | $2.94 | $27.56 |
| Distance from 52-week high | -36.10% | -27.82% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +17.65% | +113.44% |
| Average volume | 1.05M | 444.13K |
| Shares outstanding | 356.82M | 51.50M |
| Employees | 1,279 | 524 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMCR has outperformed ALVO by 17.4 percentage points over the past year.
- Alvotech is more profitable, keeping 4.8 cents of every revenue dollar as net income versus -8.9 cents for Immunocore.
- Immunocore grew revenue faster in its latest fiscal year (+28.95% vs +19.74%).
About Alvotech
ALVO stock →Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,279 employees
About Immunocore
IMCR stock →Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 524 employees
ALVO vs IMCR FAQ
Which is bigger, Alvotech or Immunocore?
Alvotech (ALVO) is larger, with a market capitalization of $2.06B compared with $1.51B for Immunocore (IMCR).
Which stock has performed better over the past year, ALVO or IMCR?
IMCR returned -12.94% over the past 12 months, compared with -30.36% for ALVO (price return, excluding dividends). Past performance does not predict future results.
Are Alvotech and Immunocore in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.